Engene Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Engene Therapeutics Inc 's ROA in the third quarter of 2026?
Engene Therapeutics Inc recorded a cumulative net loss of $-10 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -4%.

However, within the Healthcare sector 248 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jul 31 2026 quarter, so far to 224, from total ROA ranking in the second quarter of 2026 at 3208.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jul 31 2026) III. Quarter	(Apr 30 2026) II. Quarter	(Jan 31 2026) I. Quarter	(Oct 31 2025) IV. Quarter	(Jul 31 2025) III. Quarter
Y / Y Total Assets Change	17.08 %	16.08 %	-28.51 %	-28.51 %	-7.37 %
Y / Y Net Income Change	-	-	20.86 %	-	104.91 %
Net Income (TTM) in million	-10	51	-5	-10	43
Return On Assets (TTM)	-4 %	20.47 %	-2.07 %	-3.86 %	15.21 %
ENGN's Total Ranking	# 224	# 3208	# 2959	# 337	# 638
Total Assets (TTM) in million	288	308	222	222	246
Seq. Total Assets Change	-6.27 %	38.28 %	0 %	-9.67 %	-7.07 %
Seq. Net Income Change	-	1.6 %	-	-	-

ENGN's 5 Years Annual ROA >> Back to ENGN Management Effectiveness >> Compare ENGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 27
Sector	# 249
Overall	# 2894

Return On Assets Statistics
High	Average	Low
23.75 %	10.35 %	-4.01 %
(Jan 31 2025)		(Jul 31 2026)

Financial Statements
Engene Therapeutics Inc 's Assets	$ 288 million	ENGN's Balance sheet
Engene Therapeutics Inc 's Income	$ -33 million	Quarterly ENGN's Income Statement
ENGN's Income by Division		See ENGN's Income by Division

Annual Return On Assets	(Oct 31 2025) FY 2025	(Oct 31 2024) FY 2024	(Oct 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	-28.51 %	257.39 %	-	-	-
Total Assets in million	222	311	87	0	0
Y / Y Net Income Change	112.73 %	-49.67 %	-	-	-
Net Income in million	117	55	110	0	0
Annual Return On Assets	52.75 %	17.73 %	125.88 %	-	-

ENGN's 5 Years Annual ROA >> Back to ENGN Management Effectiveness >> Compare ENGN ROA to its Competitors

Comment on ENGN's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 52.75 % compared to prior year, due to annual net income growth of 112.73 % to $117.30 million, and due to decline of value in Engene Therapeutics Inc 's assets by -28.51 % to $222.39 million, compared to $222.39 a year before.

More Return On Assets Ratios
ENGN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ENGN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ENGN's Competitors
Subscribers only: Roa for Engene Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ENGN's Customers

You may also want to know
ENGN's Roi	ENGN's Inventory Turnover Ratio	ENGN's Growth Rates	ENGN's Dividend Comparisons
	ENGN's Profitability Ratios	ENGN's Asset Turnover Ratio	ENGN's Dividend Growth
ENGN's Roe	ENGN's Valuation Ratios	ENGN's Financial Strength Ratios	ENGN's Dividend Payout Ratio

Companies with similar Return On Assets at Jul 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-10T01:27:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.